Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
NCT02468284Phase 1Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Oct 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Primary endpoints: Maximum plasma concentration observed, Time of Cmax after subcutaneous administration and 1 more. Started Jul 2015; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02468284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468284.